Skip to content
Buy This GLP
← Research
Evidence

What Is IcoSema? Weekly Insulin and Semaglutide in One Shot

The EU authorized this weekly insulin icodec and semaglutide combination as Kyinsu. Its glucose, weight and hypoglycemia results depended on the comparator.

Editorial profile: Neil SandersBuy This GLP Editorial Team7 min read
Estimated HbA1c difference, by comparatorCOMBINE 1vs icodec alone−0.66COMBINE 2vs semaglutide 1.0 mg−0.44COMBINE 3vs basal-bolus insulin−0.06Pool the first and third and the I² is 98%.

IcoSema is a once-weekly injection combining basal insulin icodec with semaglutide. It received EU marketing authorization as Kyinsu on November 24, 2025, for adults with type 2 diabetes inadequately controlled on basal insulin or GLP-1 receptor agonists, alongside diet, exercise and oral diabetes medicines [5].

In October 2026, EMA’s medicines committee recommended extending that indication. The recommendation is a separate step from a change to the marketing authorization [6]. The CagriSema diabetes trials studied a different combination. CagriSema contains cagrilintide and semaglutide, with no insulin in the combination itself.

Three trials, three comparators

The first three COMBINE trials lasted 52 weeks and used different active comparators. The table reports estimated differences from those trials.

Week 52 results. COMBINE 2 shows weight changes in each group, and the other rows show weight differences.
TrialCompared withHbA1c differenceWeight
COMBINE 1, n=1,291weekly insulin icodec−0.66 points−5.59 kg difference
COMBINE 2, n=683semaglutide 1.0 mg−0.44 points+0.84 kg vs −3.70 kg
COMBINE 3, n=679basal-bolus insulin−0.06 points−6.72 kg difference
Week 52 results. COMBINE 2 shows weight changes in each group, and the other rows show weight differences.

In COMBINE 1, HbA1c fell 1.55 points on IcoSema and 0.89 points on weekly insulin icodec. The estimated difference was −0.66 points [2]. The meta-analysis reports a weight difference of −5.59 kg from this trial [1].

COMBINE 2 enrolled adults already on a GLP-1. The estimated HbA1c difference was −0.44 points versus semaglutide 1.0 mg [3]. Weight went the other way: up 0.84 kg on IcoSema, down 3.70 kg on semaglutide.

COMBINE 3 compared weekly IcoSema with daily basal-bolus therapy. The HbA1c difference was −0.06 points (95% CI −0.22 to 0.09), meeting the trial’s noninferiority criterion [4]. Weight favored IcoSema by 6.72 kg.

Why the pooled number reads 98%

A 2026 meta-analysis pooled COMBINE 1 and COMBINE 3, 1,970 people [1]. It left out COMBINE 2 for asking a different question.

The pooled HbA1c difference was −0.37 percentage points (95% CI −0.95 to 0.21). The I² was 98% [1].

The studies differed in their estimated effects. Their different insulin comparators may help explain the inconsistency. With just two trials, the individual estimates are more informative for a specific comparison [1].

What moved beyond glucose

Compared with insulin-based regimens, pooled mean differences favored IcoSema for weight (−6.10 kg) and systolic blood pressure (−2.45 mmHg). LDL cholesterol and triglycerides each had an estimated treatment ratio of 0.94 [1].

Hypoglycemia fell sharply against insulin. Severe or clinically significant episodes ran 0.14 per person-year of exposure versus 0.63 on icodec [2]. Against basal-bolus therapy they ran 0.21 versus 2.23 [4]. Compared with semaglutide alone, the trial detected no statistically significant difference [3].

Our guide to low blood sugar with insulin and GLP-1 medicines explains why what a patient takes alongside a GLP-1 affects risk. IcoSema contains insulin.

How the regimens differ

IcoSema was given weekly in all three trials. In COMBINE 3, the comparator used daily basal insulin plus mealtime insulin [4]. Those findings apply to the regimens and adults studied and do not predict how a medication change would affect an individual patient.

Frequently asked

What is IcoSema?
A weekly injection combining basal insulin icodec and semaglutide. It has EU marketing authorization as Kyinsu for type 2 diabetes.
Does IcoSema work better than insulin?
Against weekly insulin icodec alone, HbA1c fell 0.66 points more. Against basal-bolus therapy the difference was 0.06 points, which met the non-inferiority test, with 6.72 kg less weight and far fewer low-sugar episodes.
Why does the pooled analysis show 98% heterogeneity?
The I² of 98% reflects very different estimates across the two trials. Their insulin comparators differed, which may help explain the inconsistency. The pooled HbA1c difference was −0.37 percentage points, with a confidence interval that crossed zero.
Does IcoSema cause weight loss?
It depends on the comparison. Against basal-bolus insulin, weight favored IcoSema by 6.72 kg. Against semaglutide alone, weight rose 0.84 kg on IcoSema while it fell 3.70 kg on semaglutide.
Does it reduce cardiovascular risk?
The pooled analysis measured weight, blood pressure and lipids. It did not establish whether IcoSema reduces cardiovascular events.

Sources

  1. [1] Alper A, et al. (2026). Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials Cardiovascular Diabetology - Endocrinology Reports. PMID 42681675
  2. [2] Mathieu C, et al. (2025). Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial The Lancet Diabetes & Endocrinology. PMID 40482671
  3. [3] Lingvay I, et al. (2025). Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial Diabetologia. PMID 39820580
  4. [4] Billings LK, et al. (2025). Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial The Lancet Diabetes & Endocrinology. PMID 40482670
  5. [5] European Medicines Agency (2026). Kyinsu: European Public Assessment Report European Medicines Agency. Source
  6. [6] European Medicines Agency (2026). Kyinsu: opinion on variation to marketing authorisation European Medicines Agency. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence